Observational studyBMC emergency medicine2025
SVEAT score for early risk stratification of acute chest pain: a multicenter study.
Observational study in BMC emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lactate-to-albumin ratio, C-reactive protein-to-albumin ratio, and prognostic nutritional index in acute and critical care: A focused mini-review.World journal of critical care medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChest pain is one of the most common reasons for emergency department (ED) visits. This study aimed to evaluate and compare the diagnostic performance of the SVEAT score for risk stratification in patients presenting to the ED with chest pain.
methodsThis prospective, multicenter, observational study was conducted between June 1 and November 31, 2024. Adult patients presenting with chest pain were included. Exclusion criteria included trauma, pregnancy, STEMI diagnosis at presentation, unavailable follow-up, or missing data. Demographic characteristics, vital parameters, comorbidities, medications, and clinical outcomes were recorded. SVEAT and HEART scores were calculated at 0, 1, and 2 h based on original definitions. The primary outcome was the occurrence of MACE within 30 days.
resultsA total of 704 patients were included (median age 46 years (IQR 33–61), 44.6% female). MACE occurred in 157 patients (22.3%). The area under the receiver operating characteristic curve (AUC) values for the SVEAT score at 0, 1, and 2 h were 0.954, 0.954, and 0.955, respectively, and for the HEART score were 0.935, 0.937, and 0.938, respectively. For the optimal cut-off value (SVEAT > 1), the sensitivity and specificity for MACE prediction were consistently 89% and 91% across all time points. For HEART > 2, the sensitivity was 89%, 91%, and 92%, with a constant specificity of 83%.
conclusionThe SVEAT score demonstrated excellent predictive accuracy for MACE at all time points and effectively discriminated between high- and low-risk patients with chest pain. The newly identified cut-off values enhance the safe identification of low-risk patients, potentially supporting earlier discharge decisions and optimizing ED resource utilization. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.